



Subject: Foot Care*

Effective Date: February 27, 2007

Department(s): Utilization Management

Policy: Specific types of foot care, other than routine foot care as defined below, are reimbursable under Plans administered by QualCare, Inc. as delineated in this policy.

Objective: To assure proper and consistent reimbursement and to delineate the types of non-routine foot care covered by QualCare's Plans.

Procedure:

1. In patients with diabetes (**ICD-9 249.6, 250.6 ICD-10 E08.4- E13.610**), peripheral vascular disease (**ICD-9 440.0 – 440.9, 443.8, 443.9 ICD-10 I70.201- I70.91**), peripheral neuropathy (**ICD-9 356.0 – 356.9; ICD-10 G60.0-G60.9**), or other comparable conditions, in which non-professional provision of these services is likely to be hazardous, the following services are reimbursable:
 - a. Paring or cutting of corns or calluses (**HCPCS S0390**)
 - b. Trimming of toenails (**G0127**)
 - c. Routine hygienic care (**G0245 – G0247**)
2. In the absence of diabetes, peripheral vascular disease, peripheral neuropathy, or other comparable conditions, the treatments listed above, which are considered “routine foot care,” are **not reimbursable** under Plans

administered by QualCare, unless specifically included in the respective Summary Plan Description:

3. The following are reimbursable with or without one of the conditions named in paragraphs 1 and 2 above:

- a. Medical and/or surgical treatment of onychomycosis (**ICD-9 110.1, ICD-10 B35.1**)
- b. Medical and/or surgical treatment of warts (**ICD-9 078.1; ICD-10 B07.0**)

4. Treatment of onychomycosis with laser therapy, including but not limited to the Pinpointe™ laser, FootLaser™ or the Neovon laser, is considered cosmetic and is not reimbursable.

5. Treatment of onychomycosis with photodynamic therapy (PDT) is NOT reimbursable as it is considered investigational due to lack of effectiveness in the peer-reviewed literature.

References

Megna M, Fabbrocini G, Marasca C, Monfrecola G. Photodynamic Therapy and Skin Appendage Disorders: A Review. *Skin Appendage Disord.* 2017;2(3-4):166-176(Jan)

Gupta AK, Versteeg SG. A critical review of improvement rates for laser therapy used to treat toenail onychomycosis. *J Eur Acad Dermatol Venereol.* 2017;31(7):1111-1118(Jul)

Espírito-Santo GAD, Leite DP Jr, Hoffmann-Santos HD, Dias LB, Hahn RC. 1340nm LASER THERAPY FOR ONYCHOMYCOSIS: Negative Results of Prospective Treatment of 72 Toenails and a Literature Review. *J Clin Aesthet Dermatol.* 2017;10(8):56-61(Aug)

Liddell LT, Rosen T. Laser Therapy for Onychomycosis: Fact or Fiction? *J Fungi (Basel).* 2015;1(1):44-54(Apr)

Bristow IR. The effectiveness of lasers in the treatment of onychomycosis: a systematic review. *J Foot Ankle Res.* 2014;7:34(Jul)

Becker C, Bershow A. Lasers and photodynamic therapy in the treatment of onychomycosis: a review of the literature. *Dermatol Online J* 2013;19(9:19611)(Sep)

Gupta K, Simpson F. Device-Based Therapies for Onychomycosis Treatment. *Skin Therapy Letter.* 2012;17(9):4-9

Hochman LG. Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser. *J Cosmet Laser Ther* 2011;13(1):2-5.

Gupta AK, Uro M, Cooper EA. Onychomycosis therapy: past, present, future. 2010 *J Drugs Dermatol*;9(9):1109-13.

Landsman AS, Robbins AH, Angelini PF, et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. *J Am Podiatr Med Assoc*. 2010;100(3):166-77.

FDA 510(k) clearance summary for PinPointe™FootLaser™- accessed online 5/25/11 at www.accessdata.fda.gov/cdrh_docs/pdf9/K093547.pdf

FDA 510(k) clearance summary for Neovon laser accessed online 5/25/11 at www.accessdata.fda.gov/cdrh_docs/pdf7/K071815.pdf

Center for Medicare Advocacy, Inc. Medicare Provides Limited Coverage for Foot Care. Available at www.medicareadvocacy.org/Print/2008/PartB_08_03.13.Footcare.htm. Accessed 02/07/09

State of North Carolina Division of Medical Assistance. Clinical Coverage Policy No.: IC-2 Medically Necessary Routine Foot Care. Revised August 1, 2007. available at www.dhhs.state.nc.us/dma/physician/1C2.pdf. Accessed 02/07/09

American Podiatric Medical Association. Podiatric Medicine: Information From the American Podiatric Medical Association. Available at www.apma.org/doc.asp?CID=395&DID=9416&rcss=print&print=yes accessed 01/29/07

Gupta AK, Linh QT. Therapies for Onychomycosis: A Review. *Dermatol Clin* 2006;24:375-379

Theodosat A. Skin diseases of the lower extremities in the elderly. *Dermatol Clin* 2004;22:13-21

Skyler JS, Hirsch IB. Diabetes Mellitus. Ch 96 in Noble J, ed-in-chief. *Textbook of Primary Care Medicine* 3rd ed. St. Louis. Mosby. 2001

Frykberg RG. Disorders of the Foot and Ankle. Ch 130 in Noble J, ed-in-chief. *Textbook of Primary Care Medicine* 3rd ed. St. Louis. Mosby. 2001

Drafted By/Date: B. Fisher, MD; R Schachter DPM 01/31/07

Approved By/Date: QM Committee 02/27/07

Revised By/Date: B. Fisher, MD, R Schachter DPM 02/14/09

Approved By/Date: QM Committee 03/24/09
Revised By/Date: M. McNeil, MD 05/25/11
Accepted By/Date: QM Committee 06/14/11
Reviewed without Revision By/Date: M. McNeil, MD 06/20/13
Approved By/Date: QM Committee 07/23/13
Revised By/Date: M. McNeil, MD 03/10/16
Approved By/Date: QM Committee 04/19/16
Reviewed w/o Revision By/Date: MMcNeil, MD 02/05/18
Approved By/Date: QM Committee 02/20/18

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.